Synthetic glycobiology is an emerging field that combines the principles and technologies of synthetic biology and glycobiology to design, construct, and optimize biological systems to produce or regulate carbohydrate compounds. In this field, chassis refers to a modified biological system used as a basic platform for synthetic biology that allows specific genetic elements to be conveniently inserted or deleted to achieve a target function. At CD BioGlyco, our GlycoChas™ platform offers a variety of chassis for carbohydrate production. We offer a variety of chassis including but not limited to plant chassis, microalgae chassis, insect chassis, fungal chassis, bacteria chassis, and mammalian chassis. In addition, we provide Chassis Development and Production services to our clients.
Plant chassis utilize plants' natural photosynthetic capabilities and complex metabolic networks to provide a sustainable and environmentally friendly production platform for synthetic biology. CD BioGlyco uses gene editing technology to introduce or optimize glycan synthesis pathways in plants to produce various valuable carbohydrate compounds.
Microalgae chassis has the characteristics of rapid growth and high photosynthetic efficiency. CD BioGlyco uses synthetic biology methods to transform the metabolic pathways of microalgae to achieve efficient production of various carbohydrate compounds.
Insect chassis provides a unique production platform for synthetic biology. Insects have the advantages of fast reproduction and low feeding costs. CD BioGlyco uses gene editing technology to introduce a glycan synthesis pathway in insects to produce specific glycan compounds. Insect chassis has potential application value in fields such as biomedicine and food industry.
Fungal chassis plays an important role in the field of synthetic biology due to its complex metabolic network and easy genetic manipulation. CD BioGlyco achieves efficient production of various carbohydrate compounds by modifying the metabolic pathways of fungi.
Bacteria chassis is one of the most commonly used chassis organisms in synthetic biology. Bacteria have the advantages of rapid growth and easy cultivation and are suitable for large-scale production of various carbohydrate compounds. CD BioGlyco uses gene editing and metabolic engineering technologies to construct and optimize glycan synthesis pathways in bacteria to achieve efficient production of target glycans.
Mammalian chassis provides an advanced production platform for synthetic biology. Mammalian cells have a metabolic network and complex post-processing capabilities similar to humans and are suitable for the production of carbohydrate compounds related to human health. CD BioGlyco uses cell culture technology to construct and optimize carbohydrate synthesis pathways in mammalian cells. Mammalian chassis have huge application potential in the field of biomedicine.
We use gene editing, metabolic pathway engineering, introduction of heterologous pathways, optimization of the regulatory system and construction of cell factory to achieve research on synthetic glycobiology.
- Gene editing: We use the CRISPR-Cas9 gene editing tool to accurately and efficiently edit the genome of chassis organisms. This includes operations such as gene insertion, deletion, substitution, and point mutation to achieve precise regulation of carbohydrate metabolism pathways.
- Metabolic pathway engineering: We improve the production efficiency of carbohydrate compounds by modifying and optimizing the endogenous metabolic pathways of chassis organisms. This includes strategies such as enhancing the supply of precursor substances, optimizing the activity of key enzymes, and reducing the generation of by-products.
- Introduction of heterologous pathways: We introduce carbohydrate synthesis pathways from other organisms into chassis organisms to expand their carbohydrate synthesis capabilities. This requires combining enzyme genes from different sources through synthetic biology and optimizing their expression levels to ensure the efficient operation of heterologous pathways in chassis organisms.
- Optimization of the regulatory system: We construct and optimize the regulatory system to achieve precise expression of carbohydrate synthesis genes in chassis organisms. This includes utilizing regulatory elements such as promoters, terminators, and ribosome binding sites, as well as constructing dynamic regulatory networks that respond to specific environmental signals.
- Construction of cell factory: We bioconvert the chassis into an efficient cell factory for large-scale production of carbohydrate compounds. This requires in-depth research and optimization of the physiological characteristics, metabolic network, and fermentation process of chassis organisms.
Fig.1 GlycoChas™ platform. (CD BioGlyco)
In addition to offering a variety of chassis, we offer advanced cell-free system construction services, and a flexible, controllable, and efficient research and production platform in synthetic glycobiology.
The cell-free system is a system that performs biochemical reactions without intact cells. In this system, enzymes, cofactors, substrates, and other essential components required for biochemical reactions are extracted and reconstituted in a cell-free in vitro environment, thereby simulating intracellular metabolic processes.
Cell-free system construction service includes 6 basic steps: preparation of system components, the establishment of the reaction system, reconstruction of metabolic pathways, the establishment of energy regeneration system, design of dynamic regulation and feedback mechanism, and high-throughput screening and automation.
Applications
- The production of carbohydrates with high added value, such as rare monosaccharides, complex polysaccharides, and glycoconjugates, is achieved by modifying the metabolic pathways of chassis organisms.
- Chassis organisms can be used to produce biofuels such as bioethanol and butanol. Biofuel production and efficiency can be improved by optimizing the carbohydrate metabolism pathways of chassis organisms. For example, metabolic engineering could be used to modify yeast so that it can convert cheap biomass into biofuels.
- Chassis can serve as a biocatalyst for drug glycosylation in the pharmaceutical industry. It achieves site-specific glycosylation of drug molecules by introducing specific glycosyltransferases and regulatory systems. This method can not only improve the production efficiency of drugs but also reduce by-products and environmental pollution during chemical synthesis.
- Some chassis organisms degrade environmental pollutants, such as petroleum hydrocarbons, toxic metal ions, or organic pollutants. Their ability to degrade specific pollutants can be enhanced by modifying the metabolic pathways of these chassis organisms.
CD BioGlyco has the advanced GlycoChas™ platform, which integrates a variety of chassis and cell-free system construction services to provide clients with efficient, flexible, and innovative synthetic glycobiology solutions. Through the GlycoChas™ platform, we quickly customize and optimize carbohydrate synthesis pathways to meet different needs from basic research to industrial production. Please feel free to contact us at any time to discuss and create a bright future for synthetic glycobiology.
Reference
- Kightlinger, W.; et al. Synthetic glycobiology: parts, systems, and applications. ACS synthetic biology. 2020, 9(7): 1534-1562.
For research use only. Not intended for any clinical use.
Related Services
